Autoimmune encephalitis
Conditions
Interventions
Experimental group:CD20 monoclonal antibody
Control group:First-line immunotherapy
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Acute attack of one or more of the 8 core clinical manifestations: mental disturbance, memory loss, language disturbance, seizure, movement disturbance, disturbance of consciousness, autonomic dysfunction and central hypoventilation; 2. The autoimmune encephalitis antibody was clearly detected positive in CSF [CBA method: (anti-NMDAR, GABAB-RandLGI1/CASPR2 antibody)]; 3. Reasonable exclusion of other diseases; 4. It is a refractory AE, defined as: AE patients who have received first-line immune pulse therapy in the acute phase, but the treatment effect is not good (mRS score does not improve or mRS persists = 4 points), and the AE patient who intends to start immune pulse therapy again .
Exclusion criteria
Exclusion criteria: 1. Patients with a diagnosis of human immunodeficiency virus (HIV) infection, brain abscess, viral disease, cerebral malaria, brain tumor, or non-communicable central nervous system disease such as acute demyelinating encephalomyelitis (ADEM) ; 2. Patients with central nervous system infection with viruses, bacteria, fungi, parasites or Mycobacterium tuberculosis (TB); 3. Patients with encephalopathy secondary to sepsis or systemic inflammatory response syndrome; 4. Patients diagnosed with epilepsy, traumatic brain injury and/or other neurological diseases before the onset of encephalitis; 5. Other autoimmune encephalitis patients with positive serum and/or CSF laboratory tests: a-Amino 3-hydroxy-5-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor antibody Encephalitis, glutamic acid decarboxylase (GAD) antibody encephalitis; 6. Patients who lack key clinical data; 7. Pregnancy or lactation; 8. Patients with contraindications to the use of immunosuppressants: such as severe infections.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Rankin Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment; | — |
Countries
China
Contacts
Public ContactZhen Hong
West China Hospital, Sichuan University
Outcome results
None listed